Maravai LifeSciences and GTCR Complete Acquisition of Solulink Commercial Assets
SAN DIEGO, CA (December 27, 2016) Maravai LifeSciences (“Maravai”), a leader in providing specialty reagents to life sciences researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced it has completed the acquisition of the commercial assets of Solulink Incorporated (“Solulink”). The Solulink assets will be part of the product portfolio offered by Maravai’s TriLink BioTechnologies (“TriLink”) subsidiary.
Commenting on the acquisition, Rick Hogrefe, CEO of TriLink, noted “We have had a long relationship with Solulink and have manufactured and commercialized their products for several years in partnership with them. We are thrilled to continue to offer these products under our sole ownership.”
Maravai is a portfolio company of GTCR. Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the financial services & technology, healthcare, and information services & technology industries. GTCR pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $15 billion in over 200 companies.
The Maravai portfolio of companies includes Vector Laboratories, Cygnus Technologies and TriLink BioTechnologies.